Multiple Myeloma Coverage from Every Angle

Paul G. Richardson, MD, on Isatuximab Plus Pomalidomide and Low-Dose Dexamethasone in Multiple Myeloma

Posted: Wednesday, July 14, 2021

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses phase III results from the ICARIA-MM study, which showed that isatuximab plus pomalidomide improved the time to next treatment as well as disease progression on first subsequent therapy or death compared with pomalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. There was also a strong trend in overall survival benefit reported with the addition of isatuximab.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.